Search API | Vax-Before-Travel

Search API

0 min read

Pfizer Inc. today reported $354 million in Comirnaty® vaccine revenue in Q1 2024, marking an 88% drop from the previous year's Q1.

On May 1, 2024, Pfizer explained this decrease was driven largely by lower contractual deliveries and demand in international markets and lower U.S. volumes, reflecting the anticipated seasonality of demand for vaccinations and as certain markets, including the U.S., transition to traditional commercial market sales.

Dr. Albert Bourla, Chairman and Chief Executive Officer, stated in a press release, "We delivered strong performance in our non-COVID product portfolio in the first quarter of 2024, including increased revenue from several of our recent commercial launches and acquired products, as well as robust year-over-year growth for several key in-line brands."

"Our Paxlovid® revenues in the quarter indicate a successful transition into the commercial marketplace in the U.S. and a demonstrated trust in the brand."

"Overall, I am encouraged by a well-executed quarter, setting the tone for the year. Pfizer's commercial leadership is focused on data-driven opportunities across several key growth brands, both in the U.S. and internationally, and we intend to build on this positive momentum in the quarters ahead."

Results from a recent survey published by the journal Nature indicate this negative trend may continue in 2024.

On April 29, 2024, this survey in 23 countries was taken in October 2023. t found a lower intent to get a COVID-19 booster vaccine (71.6%) compared with 2022 (87.9%).

Trust in vaccine information sourced each averaged less than 7 on a 10-point scale with one’s own doctor or nurse and the World Health Organization, averaging 6.9 and 6.5, respectively.

'Our findings emphasize that vaccine hesitancy and trust challenges remain for public health practitioners, underscoring the need for targeted, culturally sensitive health communication strategies,' wrote these researchers.

Vaccine Treats:

COVID-19

Image:

Image Caption:

by Alessandro D'Andrea

Live Blog Update Author:

Don Hackett

Location Tags:

New York

Vaccine:

Comirnaty COVID-19 Vaccine

Pivya (pivmecillinam) Tablets for Urinary Tract Infections (UTI)

Pivya™ (pivmecillinam) Tablets for Uncomplicated Urinary Tract Infections (UTI) Clinical Trials, Dosage, Indication, Side Effects

UTILITY therapeutics Ltd. pivmecillinam (Pivya™, Selexid, Melysin, Coactab) penicillin class antibacterial tablet approved for the treatment of female adults with uncomplicated urinary tract infections (UTIs) caused by susceptible isolates of Escherichia coli, Proteus mirabilis, and Staphylococcus saprophyticus. Pivmecillinam is a prodrug of the beta-lactam antibiotic mecillinam, a pivaloyloxymethyl ester of amdinocillin that is well absorbed orally but broken down to amdinocillin in the intestinal mucosa. Pivmecillinam interferes with the biosynthesis of the bacterial cell wall; however, its activity is slightly different from that of other penicillins and cephalosporins. Pivya overcomes antimicrobial resistance by killing bacteria to resist the effects of a drug.

On April 24, 2024, the U.S. Food and Drug Administration (FDA) approved Pivya tablets for treating female adults with uncomplicated UTIs. The New Drug Application submitted to the FDA comprised six clinical studies supporting the efficacy and 12 clinical studies supporting the safety of PIVYA. Through a sequence of interactions with the FDA, UTILITY has reanalyzed all available data according to the FDA 2019 uncomplicated UTI guidance. The clinical data support first-line positioning due to its benign safety profile and consistent efficacy.

In the clinical trial comparing Pivya to placebo, 62% of the 137 subjects who received Pivya achieved the composite response compared to 10% of the 134 who received placebo. In the clinical trial comparing Pivya to another oral antibacterial drug, 72% of the 127 subjects who received Pivya achieved composite response compared to 76% of the 132 who received the comparator drug. In the phase 4 clinical trial comparing Pivya to ibuprofen, 66% of the 105 subjects who received Pivya achieved a composite response compared to 22% of the 119 who received ibuprofen. Pivya was granted FDA Priority Review and Qualified Infectious Disease Product Designations.

UTILITY is a privately held pharmaceutical development company. At UTILITY, we are committed to providing reliable and transparent information about our business, development programs, and regulatory progress in a clear and timely manner. For more information, please contact Tom Hadley, President and CEO. Email: [email protected]

Pivya™ (pivmecillinam) Availability

UTILITY has exclusive U.S. commercial rights to two European-approved antibiotics, pivmecillinam and mecillinam. Pivya is available in Europe and is expected to be available in the U.S. in 2025. Pivmecillinam has been approved in Canada, Denmark, the United Kingdom, and other countries.

Pivya (pivmecillinam) Indication

In the U.S., UTIs are a severe public health problem that is becoming increasingly more difficult to manage. A UTI is an infection of the urinary tract that can occur at different points in the urinary tract, including the Bladder, Kidneys, Ureters, or Urethra. The uUTI treatment is recommended for first-line use in many countries. It is part of the Infectious Diseases Society of America (IDSA) and the European Society for Microbiology and Infectious Diseases guidelines. A 2022 World Health Organization report found that more than 20% of Escherichia coli isolates are the most common cause of UTIs.

Pivya (pivmecillinam) Efficacy

In a phase 4 clinical trial comparing Pivya to ibuprofen, 66% of the 105 subjects who received Pivya achieved a composite response compared to 22% of the 119 who received ibuprofen.

Pivya (pivmecillinam) Format

Pivmecillinam (oral) and mecillinam (IV, hospital setting) are unique classes of antibiotics with potent in vitro and in vivo activity against the most common bacteria in UTIs, including resistant strains such as ESBL-producing E coli. Mecillinam (IV) solely targets penicillin-binding protein-2 (PBP-2) in the cell wall of gram-negative bacteria.17,21 This unique mechanism leads to favorable stability against β-lactamase hydrolysis compared to other penicillins.

Pivya™ (pivmecillinam) Side Effects

Pivya's adverse effect profile is similar to that of other penicillins; the most common side effects include nausea and diarrhea. Patients should not use Pivya if they have a known history of severe hypersensitivity to Pivya or other beta-lactam antibacterial drugs. Patients should also not use Pivya if they have primary or secondary carnitine deficiency resulting from inherited disorders of mitochondrial fatty acid oxidation and carnitine metabolism or if they suffer from porphyria. Pivya comes with specific warnings and precautions, such as hypersensitivity reactions, severe cutaneous adverse reactions, carnitine depletion, Clostridioides difficile-associated diarrhea, and interference with a newborn screening test for isovaleric acidemia, a rare metabolic disorder.

Pivya™ (pivmecillinam) News

April 24, 2024 - “Uncomplicated UTIs are a prevalent condition impacting women and one of the most frequent reasons for antibiotic use,” said Peter Kim, M.D., M.S., director of the Division of Anti-Infectives in the FDA’s Center for Drug Evaluation and Research. “The FDA is committed to fostering new antibiotic availability when they prove safe and effective, and Pivya will provide an additional treatment option for uncomplicated UTIs.”

January 17, 2024 - UTILITY therapeutics Ltd. announced a private financing led by the AMR Action Fund.

Pivya™ (pivmecillinam) Clinical Trials

PIVYA™ (pivmecillinam, oral) research comprises six clinical studies (phase 3) supporting the efficacy. In the clinical trial comparing pivmecillinam to another oral antibacterial drug, 72% of the 127 participants who received pivmecillinam achieved composite response compared to 76% of the 132 who received the comparator drug.

0 min read

Manufacturer:

UTILITY therapeutics Ltd.

Reviewer:

Robert Carlson, MD

Vaccine:

Pivya (pivmecillinam) Tablets for Urinary Tract Infections (UTI)

VIS:

PDF

Availability:

2025 in the USA

Generic:

Pivmecillinan

Drug Class:

Tablet

Clinical Trial Phase III:

Pivmecillinam Hydrochloride Tablets in the Treatment of Uncomplicated Urinary Tract Infection

Clinical Trial Phase IV:

Phase 4 study

Condition:

Urinary Track Infection (UTI)

Availability Link:

US FDA

Last Reviewed:

Saturday, August 2, 2025 - 07:10

Brand:

Pivya

ChEMBL ID:

C21H33N3O5S

Accession Number:

Pivmecillinam

Status:

Approved

Manufacturer Country ID:

FDA First In Class:

Yes

Ingredients:

Countries:

UNII:

Urinary Tract Infection (UTI) Vaccine and Treatment

Urinary Tract Infection (UTI) Vaccine and Treatments 2025

Urinary tract infections (UTIs) are among the most common bacterial infections, affecting hundreds of millions of people worldwide each year. Most UTIs are caused by uropathogenic E. coli (E. coli). Less common pathogens, such as Enterococcus faecalis and other enterococci, cause infections by infecting an abnormal or catheterized urinary tract. As of 2025, patients with Uncomplicated and Recurrent UTI in the United States require prophylactic antibiotic regimens, as vaccines are not yet available.

UTIs place an economic burden on the U.S. healthcare system, with direct and indirect costs estimated at around $3.5 billion annually. In England, the Hospital Episode Statistics for 2023-2024 indicate that there were nearly 190,000 hospital admissions for urinary tract infections (UTIs), a 9% increase from the previous year. These admissions accounted for 1.2 million bed-days, with an average hospital stay of 6 days, and cost over £600 million. Most cases affected older adults (aged 70 and above) and women. This situation highlights UTIs as a significant, often preventable, burden on the NHS.

As of 2025, the U.S. Centers for Disease Control and Prevention (CDC) says most UTIs can be treated with antibiotics prescribed by a healthcare professional. European guidelines recommend an immunoreactive (vaccine) strategy for preventing Urinary tract infections (UTIs). The Infectious Diseases Society of America announced in February 2025 that it accepts comments on the updated 2025 Guideline on the Management and Treatment of Complicated Urinary Tract Infections (cUTI). This update provides clinical practice guidelines for patients with cUTI, with and without sepsis.

On November 4, 2024, the JAMA Network published a Consensus Statement for the development of UTI clinical guidelines. However, most topics relating to the prevention, diagnosis, and treatment of UTIs lack high-quality prospective data. A mini-review published in January 2025 summarizes the current state of UTI diagnostics, covering both existing and emerging technologies, including rapid molecular-based pathogen identification, next-generation sequencing, and advanced antimicrobial susceptibility testing. However, these methods present challenges, and as they are implemented, they will need to adapt to new concepts to avoid misdiagnosis and overtreatment.

Urinary Tract Infection (UTI) Vaccines

As of 2025, international travelers seeking a rUTI vaccine appointment can submit a request to PassportHealth in London, England.

Immunotek S.L. Uromune™ (MV140), an oral spray for recurrent urinary tract infections, has been approved for adults in countries such as Mexico and the United Kingdom.

Uro-Vaxom® (OM-89) is an immunostimulant vaccine consisting of an oral tablet with 18 heat-killed strains of E coli bacteria. Uro-Vaxom activates the immunocompetent cells of the intestinal lining Peyer's plaques). In humans, Uro-Vaxom stimulates white blood cells and promotes the production of antibodies, thereby helping to prevent urinary tract infections (UTIs). A review found that the risk ratio for developing at least one UTI in the female population was significantly lower in the OM-89 group (risk ratio, 0.61; 95% confidence interval, 0.48–0.78), and the mean number of UTIs was approximately half that of the placebo group. It has been used in Europe with minimal documented adverse events and is recommended by the European Association of Urology.

StroVac® (Solco-Urovac, Strovac) is a vaccine against UTIs that contains 10 bacterial strains known to cause them. It acts not only through the adaptive immune system but also by stimulating the innate immune system. It is available in Germany, not in the USA.

Urinary Tract Infection (UTI) Vaccine Candidates

A Research Article published in March 2021 - Local induction of bladder Th1 responses to combat urinary tract infections - concluded that intravesical vaccination with one or more UPEC antigens to induce bladder Th1 responses represents a superior strategy to combat UTIs, especially in UTI-prone subjects.

Baxiva's proprietary conjugation platform streamlines the development of multivalent vaccines targeting the serotype-specific polysaccharides of Gram-negative bacteria, including capsule and O antigens. The multivalent vaccine targets the most common serotypes associated with invasive ExPEC infections.

Urinary Tract Infection (UTI) Treatment

There are approximately 40 million uUTI prescriptions written annually in the U.S., and approximately 1% of those UTI infections are caused by pathogens resistant to common oral antibiotics. The four leading oral antibiotic treatments for uUTI (slide #6) account for approximately 75% of the prescription market, but have resistance rates of 20% or higher.

GSK plc announced on March 25, 2025, that the U.S. FDA approved Blujepa (gepotidacin), a topoisomerase inhibitor antibiotic for the treatment of uUTIs. Blujepa is the first in a new class of oral antibiotics for uUTIs in nearly 30 years.

Iterum Therapeutics announced in August 2025 that Orlynvah™ (sulopenem etzadroxil and probenecid), a broad-spectrum oral penem antibiotic that's indicated for treating uUTIs caused by certain bacteria (Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis) in adult women, is the first U.S. FDA-approved oral penem antibiotic commercially available in the United States.

Spero Therapeutics, Inc. and GSK plc announced on May 28, 2025, that the pivotal, multi-country, Phase 3 PIVOT-PO trial evaluating tebipenem HBr ((TBP-PI-HBr) an investigational oral treatment for complicated urinary tract infections (cUTIs), including pyelonephritis, met its primary endpoint and will stop early for efficacy (NCT06059846). The decision follows a recommendation from the Independent Data Monitoring Committee, which completed a pre-specified interim analysis of data from 1,690 patients enrolled in the trial.

Pivya ™ (Pivmecillinam) is an extended-spectrum penicillin antibiotic and a U.S. FDA-approved oral prodrug of mecillinam. Pivya has a unique mechanism of action that targets the penicillin-binding protein 2 (PBP-2) in the cell walls of Gram-negative bacteria. The Pivya tablet has been used throughout Europe for years and is expected to be available in the U.S. in 2025.

ORLYNVAH™ (sulopenem etzadroxil and probenecid) is a U.S. FDA-approved novel oral penem antibiotic for the treatment of uUTIs caused by the designated microorganisms Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis in adult women. Orlynvah is taken as one oral tablet twice daily for 5 days.

RECCE® 327 (R327) is an investigational synthetic anti-infective developed for treating severe, potentially life-threatening infections caused by Gram-positive and Gram-negative bacteria, including the full suite of ESKAPE pathogens, even in their superbug forms.

In various clinical trials, Locus Biosciences is developing LBP-EC01, a CRISPR-enhanced bacteriophage therapy for the treatment of UTIs and other infections caused by E. coli. It is a bacteriophage cocktail engineered with a CRISPR-Cas3 construct targeting the E. coli gene. It is not a broad-spectrum antibacterial that kills various bacterial species. The precision medicine product works through a unique dual mechanism of action, utilizing both the natural lytic activity of the bacteriophage and the DNA-targeting activity of CRISPR-Cas3.

UTI Tests

A Viewpoint published by The JAMA Network on May 5, 2025, stated urinary nitrites provide diagnostic redundancy in confirming the presence of bacteriuria at best and promote the unnecessary use of antibiotics in asymptomatic patients at worst. Future research should examine the effects of suppressing the nitrite result from the urinary dipstick to determine the downstream impact on antimicrobial prescribing. Additionally, future research should focus on refining diagnostic techniques to distinguish between true UTIs and symptomatic bacteriuria. We believe urinary nitrites should no longer be used to diagnose UTI in pediatric or adult patients.

7 min read

Reviewer:

Robert Carlson, MD

Last Reviewed:

Thursday, December 11, 2025 - 09:05

Description:

Urinary Tract Infection (UTI) Vaccines and Treatments are available in 2025

Vaccine:

Uromune MV140 Urinary Tract Infection Vaccine

0 min read

Recce Pharmaceuticals Ltd. today announced an Independent Safety Committee approved an increase in dosing to 4,000mg over a fast infusion of 30 minutes in a Phase I/II clinical trial evaluating its lead candidate, RECCE® 327 (R327).

The Company says it identified 30 minutes as the optimum infusion time and increased to a higher concentration per regulatory expectations to investigate R327’s high concentration potential.

“We’re thrilled the independent safety committee has unanimously clearly an increased R327 dose to 4,000mg, over a 30-minute fast IV infusion,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals, in a press release on April 30, 2024.

“The ability to administer high concentrations of a broad-spectrum anti-infective underscores the potential of a novel treatment for millions of patients worldwide with urinary tract infections (UTI) or urosepsis each year.”

Dosing has successfully achieved Minimum Inhibitory Concentration activity among existing clinical samples. The Company has now dosed 3,000mg at multiple infusion times: 15, 20, 30, 45 minutes, and 1 hour.

In accordance with the study protocol, the efficacy of R327 via IV administration will be made available at the completion of the ACTRN12623000448640 trial.

Recce’s New Class of Synthetic Anti-Infectives have a universal mechanism of action with the ability to overcome hyper-cellular mutation of bacteria and viruses. RECCE® 327 is not a preventive vaccine and is not approved for use in humans in any country.

The investigational recurrent UTI vaccine MV140 is available in Australia and various countries in 2024.

Vaccine Treats:

Urinary Track Infection(UTI)

Image:

Image Caption:

Recce Pharmaceuticals 2024

Live Blog Update Author:

Karen McClorey Hackett

Location Tags:

Sydney

Vaccine:

RECCE 327 Urinary Tract Infection (UTI) Treatment

Malaria Carrying Mosquitoes Return to Italy's Coast

Malaria vaccines are available in 2024

April 30, 2024

Fact checked by Robert Carlson, MD

0 min read

Although there is no approved vaccine to prevent norovirus, it is estimated that approximately 21 million people in the United States are infected with this virus every year, including about 15% of children under the age of 5.

While pediatric deaths resulting from norovirus are rare in the U.S., they are more common in developing countries.

Nevertheless, the economic burden of norovirus in the United States alone is estimated to be $10.6 billion annually.

A recently completed Phase I trial, partially funded by the Bill & Melinda Gates Foundation, included immunogenicity measures.

On April 30, 2024, Vaxart, Inc. announced that it had completed the topline analysis evaluating the Company's orally administered bivalent GI.1/GII.4 norovirus vaccine candidate.

The VXA-NVV-108 clinical trial focused on vaccinating lactating mothers.

Antibodies to norovirus rose on average four-fold for the G1.1 virus strain and six-fold for the GII.4 virus strain in the breast milk of lactating mothers who received the Vaxart vaccine candidate in the high dose group.

Furthermore, there were no vaccine-related serious adverse events, no dose-limiting pharmacotoxicity, and no new onset of chronic illness was observed through the active period.

"This is an important step forward as we drive toward a vaccine candidate that may make it possible for mothers to protect their children against this highly contagious – and potentially lethal – virus."

"It can be difficult to immunize the youngest children mucosally because the immune system is still developing."

"Passive transfer of antibodies from mothers to infants via breast milk is an innovative approach to potentially improve infection resistance in infants," said Dr. James F. Cummings, Vaxart's Chief Medical Officer, in a press release.

As of late April 2024, the World Health Organization has not pre-qualified any norovirus vaccine candidate.

Vaccine Treats:

Norovirus

Image:

Image Caption:

By Samuel Lee

Live Blog Update Author:

Karen McClorey Hackett

Location Tags:

San Francisco

Vaccine:

Vaxart Norovirus Oral Bivalent Vaccine

0 min read

Repertoire® Immune Medicines announced today that it has entered a multi-year strategic collaboration with Bristol Myers Squibb to develop tolerizing vaccines for up to three autoimmune diseases.

Repertoire is developing tolerizing vaccines as a new class of programmable medicines for patients with autoimmune diseases.

These vaccines have the potential to re-establish immune homeostasis, leading to durable disease remission in the absence of generalized immune suppression, thereby overcoming the limitations of today's medicines and transforming the lives of patients who have been diagnosed with an autoimmune disease.

The collaboration aims to develop efficacious, selective, and durable treatments for patients suffering from autoimmune disease by resetting the immune system.

Repertoire will lead all activities through to development candidate nomination, while BMS will lead clinical development, regulatory affairs, and commercialization of the tolerizing vaccines under an exclusive worldwide license.

Repertoire will utilize its T cell receptor (TCR)-epitope discovery platform, DECODE, and its proprietary lipid nanoparticle delivery technology to discover and develop the tolerizing vaccine development candidates.

In addition, it will deploy DECODE to monitor immune responses to the tolerizing vaccines in patients during clinical development to provide key insights into the pharmacodynamic effect of the vaccines.

"This agreement is a recognition of the transformative power of Repertoire's DECODE platform to discover and develop programmable T cell targeted immune medicines," said Torben Straight Nissen, Ph.D., CEO of Repertoire and Executive Partner of Flagship Pioneering, in a press release on April 29, 2024.

"We are excited to collaborate with Bristol Myers Squibb to combine their leadership in immunology with our unique ability to discover key disease-associated epitopes in patients with autoimmune diseases. This collaboration enables us to serve patients suffering from autoimmune diseases by translating our DECODE discoveries into potentially transformative medicines that address the underlying cause of their disease."

Under the terms of the agreement, Repertoire will receive an upfront payment of $65 million and up to $1.8 billion for achieving development, regulatory, and commercial milestones in addition to receiving tiered royalties.

Vaccine Treats:

Rheumatoid Arthritis

Image:

Image Caption:

Repertoire® Immune Medicines

Live Blog Update Author:

Don Hackett

Location Tags:

Cambridge

X Accurately Corrects Vaccine Misinformation by 97%

X Community Notes corrects COVID-19 vaccine misinformation

April 29, 2024

Fact checked by Robert Carlson, MD

0 min read

Merck today announced results from STRIDE-10, a Phase 3 trial evaluating V116, the company’s investigational, adult-specific 21-valent pneumococcal conjugate vaccine.

Key results from the study include:

V116 elicited immune responses that were noninferior compared to PPSV23 for the 12 serotypes (or strains) common to both vaccines, as measured by serotype-specific opsonophagocytic activity (OPA) geometric mean titers (GMTs) at Day 30.

Immune responses elicited by V116 were superior for the nine serotypes included in V116 but not PPSV23, as measured by OPA GMT ratios at Day 30, and superior for eight of nine serotypes unique to V116 compared to PPSV23, as measured by the proportions of participants with ≥4-fold rise in immune responses.

V116 had a safety profile comparable to PPSV23.

“Invasive pneumococcal disease and pneumococcal pneumonia represent significant public health challenges, particularly among older adult populations and those with risk conditions,” said Dr. Walter Orenstein, professor emeritus of medicine, epidemiology, global health and pediatrics at Emory University and member of Merck’s Scientific Advisory Committee, in a press release on April 29, 2024.

“These positive results show that V116 has the potential to help prevent invasive pneumococcal disease among adult populations.”

In addition to the clinical data on V116, Merck also presented findings that suggest V116 may help to reduce the health and economic burden associated with invasive pneumococcal disease and non-bacteremic pneumococcal pneumonia among adults in France, Sweden, Spain, and the Netherlands.

Vaccine Treats:

Pneumococcal

Image:

Image Caption:

by NeShea Jenifer

Live Blog Update Author:

Don Hackett

Location Tags:

Rahway

Vaccine:

V116 Pneumococcal Conjugate Vaccine

0 min read

With the creation of efficacious cancer prevention vaccines to target human papillomavirus (HPV) in the first decade of this century, the World Health Organization (WHO) set an ambitious target to lower cervical cancer incidence and mortality by 30% by 2030.

While the WHO targets are aspirational, no country has yet verified that it has reached them.

A presentation by Professor Suzanne Garland at this year's ESCMID Global Congress revealed that even though the evidence is clear and continues to build that HPV vaccination is reducing cervical cancer incidence and mortality and HPV-related disease, there are high variations in coverage globally.

Prof Garland reviewed the WHO Dashboard data, which shows that of 194 reporting countries, 137 (71%) have HPV in their national vaccination programs.

The WHO database shows that the average full vaccine coverage is 44% globally.

Specifically, it shows that Canada, Ireland, Sweden, Spain, and Portugal have full vaccination coverage above 70%, while the USA and Germany trail behind at 50-70%.

Of the HPV national programs reporting to the end of 2023, 42% are for both sexes, while 58% are for girls only.

Globally, 21% of girls have received at least one dose of HPV vaccine by age 15, which has steadily increased from 4% in 2010.

Prof Garland concluded in a press release on April 27, 2024, "Vaccination is a critical component of the global strategy to eliminate cervical cancer as a public health problem."

"There is strong and growing evidence on effectiveness against cervical cancer, with rates falling steadily as vaccination takes effect."

"Scaling up vaccine access and coverage globally is critical to reduce inequities between and within countries."

In the United States, several states are reaching a broad number of boys and girls, while others are lagging.

For example, Texas's HPV vaccination rate for children ages 13–17 is below the national average, ranking 48th out of 50 states and the District of Columbia in 2021.

In 2021, 51.5% of Texas teens completed the HPV vaccine series.

As of April 29, 2024, HPV vaccines are available at clinics and pharmacies in the U.S.

Vaccine Treats:

HPV Cancers

Image: